Document Detail


Teduglutide Reduces Need for Parenteral Support Among Patients with Short Bowel Syndrome with Intestinal Failure.
MedLine Citation:
PMID:  22982184     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND & AIMS:: Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion. These factors could increase fluid and nutrient absorption in patients with short-bowel syndrome with intestinal failure (SBS-IF). We performed a prospective study to determine whether teduglutide reduces parenteral support in patients with SBS-IF. METHODS:: We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n=43) or placebo (n=43), once daily. Parenteral support was reduced if 48-hour urine volumes exceeded baseline values by ≥10%. The primary efficacy endpoint was number of responders (patients with >20% reduction in parenteral support volume, from baseline, at Weeks 20 and 24). RESULTS:: There were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (13/43 [30%], P =.002). At Week 24, the mean reduction in parenteral support volume in the teduglutide group was 4.4±3.8 L/wk (baseline, 12.9±7.8 L/wk), compared with 2.3±2.7 L/wk (baseline, 13.2±7.4 L/wk) in the placebo group ( P <.001). The percentage of patients with ≥1-day reduction in the weekly need for parenternal support was greater in the teduglutide group (21/39 [54%]) than in the placebo group (9/39 [23%], P =.005). Teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass. The distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide (n=2) or placebo (n=3). CONCLUSIONS:: Twenty-four weeks of teduglutide treatment was generally well tolerated in patients with SBS-IF. Treatment with teduglutide reduced volumes and numbers of days of parenteral support for patients with SBS-IF. (ClinicalTrials.gov Identifier: NCT00798967).
Authors:
Palle B Jeppesen; Marek Pertkiewicz; Bernard Messing; Kishore Iyer; Douglas L Seidner; Stephen J D O'Keefe; Alastair Forbes; Hartmut Heinze; Bo Joelsson
Related Documents :
12854104 - Randomized clinical trials to determine the role of topical glyceryl trinitrate in peri...
16865614 - Complication rate lower after percutaneous endoscopic gastrostomy than after surgical g...
6438014 - Effects of early nutritional support in patients with abdominal trauma.
16770284 - Nutritional supplementation decreases hip fracture-related complications.
8420094 - Balloon expanded titanium prostatic urethral stent.
22119854 - A randomised comparison of cartomerge vs. navx fusion in the catheter ablation of atria...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-11
Journal Detail:
Title:  Gastroenterology     Volume:  -     ISSN:  1528-0012     ISO Abbreviation:  Gastroenterology     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374630     Medline TA:  Gastroenterology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Medical Gastroenterology, Rigshospitalet, Copenhagen, Denmark. Electronic address: Bekker@dadlnet.dk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Similar efficacies of biliary, with or without pancreatic, sphincterotomy in treatment of idiopathic...
Next Document:  GABAB receptor activation attenuates the stimulant but not mesolimbic dopamine response to ethanol i...